Stay updated on Nivo+Ipi +/- SBRT in Metastatic MCC Clinical Trial
Sign up to get notified when there's something new on the Nivo+Ipi +/- SBRT in Metastatic MCC Clinical Trial page.

Latest updates to the Nivo+Ipi +/- SBRT in Metastatic MCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference2%
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe ClinicalTrials.gov data ingest will be modernized in June 2025, with an opportunity for API users to provide input before implementation.SummaryDifference2%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check75 days agoChange DetectedThe page has been updated to include specific details about the study of nivolumab and ipilimumab for Merkel Cell Carcinoma, including the randomization of participants and the involvement of Bristol-Myers Squibb as a collaborator. The previous version's detailed study purpose and extensive inclusion/exclusion criteria have been removed.SummaryDifference25%
- Check83 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and changed the date from March 25, 2025, to February 20, 2025.SummaryDifference0.5%
Stay in the know with updates to Nivo+Ipi +/- SBRT in Metastatic MCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivo+Ipi +/- SBRT in Metastatic MCC Clinical Trial page.